Samsung Biologics Co. Ltd.
Samsung Biologics Co. Ltd.
07/27/2025 | Press release | Distributed by Public on 07/27/2025 23:06
Analytical strategies for impurity control in antibody-drug conjugates
UPDATE |July 28, 2025
Analytical strategies for impurity control in antibody-drug conjugates
- COPY
Controlling impurities is foundational to the safe and effective development of antibody-drug conjugates.
By integrating advanced techniques, Samsung Biologics provides a robust impurity control platform that supports high drug-to-antibody ratio precision, accurate free drug quantification, and reliable residual solvent detection. These capabilities not only mitigate risk and enhance product quality, but also enable efficient, scalable development that keeps pace with regulatory expectations and accelerates the path to market.
Controlling impurities is foundational to the safe and effective development of antibody-drug conjugates.
By integrating advanced techniques, Samsung Biologics provides a robust impurity control platform that supports high drug-to-antibody ratio precision, accurate free drug quantification, and reliable residual solvent detection. These capabilities not only mitigate risk and enhance product quality, but also enable efficient, scalable development that keeps pace with regulatory expectations and accelerates the path to market.
Attached
- Analytical strategies for impurity control in antibody-drug conjugates
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article
- COPY
Back to List
Samsung Biologics Co. Ltd. published this content on July 27, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 28, 2025 at 05:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]